RPG Life Sciences Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, following a Board meeting held on April 29, 2026. The company reported a revenue from operations of ₹176.89 Crores for the quarter ended March 31, 2026, representing a decrease of 1.74% from ₹180.03 Crores in the previous quarter (QoQ) but a significant increase of 23.62% from ₹143.09 Crores in the corresponding quarter of the previous year (YoY). Profit for the period stood at ₹29.90 Crores, reflecting a 35.11% increase from ₹22.13 Crores in the preceding quarter and a decrease compared to ₹117.35 Crores in the same period last year, which had been impacted by exceptional items. The Board also recommended a dividend of ₹24 per equity share (300%) for the financial year 2025-26.

RPG Life Sciences Limited, a part of the RPG Group, is an integrated pharmaceutical company operating in the domestic and international markets. The company is engaged in the manufacturing and marketing of bulk drugs (APIs) and pharmaceutical formulations. In a strategic move during the quarter, the company appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a five-year term starting April 29, 2026. Additionally, the Board has approved the transfer of its API division to a wholly-owned subsidiary, RPG Active Pharma Limited, to streamline operations.